Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)
February 24, 2023 10:02 AM EST
R&D

Gala­pa­gos goes 0-for-3 on in­flam­ma­tion pro­gram as it cuts an ear­ly-stage can­di­date

Lei Lei Wu

News Reporter

Gala­pa­gos has cut an­ti-in­flam­ma­to­ry drug can­di­date GLPG4399 fol­low­ing the com­ple­tion of an ear­ly-stage healthy vol­un­teer tri­al, ac­cord­ing to its 2022 an­nu­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times